Literature DB >> 12609716

Introduction of wild-type p53 enhances thrombospondin-1 expression in human glioma cells.

Hironobu Harada1, Kou Nakagawa, Masahiro Saito, Shohei Kohno, Shigeyuki Nagato, Koji Furukawa, Yoshiaki Kumon, Katsuyuki Hamada, Takanori Ohnishi.   

Abstract

Malignant gliomas are distinguished from low-grade gliomas by their intense angiogenesis. In gliomas, p53 is the most frequently altered gene and is involved in the early phase of glioma development. In contrast, homozygous p16 gene deletion is more common in high-grade gliomas. In order to understand the mechanism by which gliomas become more angiogenic during the malignant transformation, we examined the relationship between thrombospondin-1, a negative regulator in angiogenesis, and these tumor suppressor genes in malignant gliomas. Human glioma cell line U-251 MG, which has mutated p53 and deleted p16, was transduced with recombinant replication-defective adenovirus vectors containing the cDNA of wild-type p53, p16, and p21. Only the induction of wild-type p53 enhanced expression of thrombospondin-1 mRNA and the protein in U-251 MG cells. Furthermore, thrombospondin-1 that was secreted in the culture medium was significantly increased (3.8-fold) as compared with that of the viral control 36 h after infection with Ad5CMV-p53. In the presence of wild-type p53 plasmid DNA, the promoter activity was increased 7.4-fold as compared with an empty expression vector control. These studies may suggest that mutation of p53 gene endows gliomas with an angiogenic phenotype by reducing thrombospondin-1 production as well as enhancing the angiogenesis inducers in the early phase of malignant progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12609716     DOI: 10.1016/s0304-3835(02)00592-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

Review 1.  Role of Matricellular Proteins in Disorders of the Central Nervous System.

Authors:  A R Jayakumar; A Apeksha; M D Norenberg
Journal:  Neurochem Res       Date:  2016-11-23       Impact factor: 3.996

Review 2.  Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.

Authors:  Tanya A Rege; Constance Y Fears; Candece L Gladson
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

3.  Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes.

Authors:  Chih-Jian Lih; Wensheng Wei; Stanley N Cohen
Journal:  Genes Dev       Date:  2006-07-17       Impact factor: 11.361

Review 4.  Invoking the power of thrombospondins: regulation of thrombospondins expression.

Authors:  Olga Stenina-Adognravi
Journal:  Matrix Biol       Date:  2014-02-25       Impact factor: 11.583

Review 5.  New molecular targets in angiogenic vessels of glioblastoma tumours.

Authors:  Joshua C Anderson; Braden C McFarland; Candece L Gladson
Journal:  Expert Rev Mol Med       Date:  2008-08-07       Impact factor: 5.600

6.  Anti-angiogenesis effect of 3'-sulfoquinovosyl-1'-monoacylglycerol via upregulation of thrombospondin 1.

Authors:  Kayo Matsuki; Atsushi Tanabe; Ayumi Hongo; Fumio Sugawara; Kengo Sakaguchi; Nobuaki Takahashi; Noriyuki Sato; Hiroeki Sahara
Journal:  Cancer Sci       Date:  2012-06-20       Impact factor: 6.716

7.  New insights into estrogenic regulation of O6-methylguanine DNA-methyltransferase (MGMT) in human breast cancer cells: Co-degradation of ER-α and MGMT proteins by fulvestrant or O6-benzylguanine indicates fresh avenues for therapy.

Authors:  Ameya Paranjpe; Nathan I Bailey; Santhi Konduri; George C Bobustuc; Francis Ali-Osman; Mohd A Yusuf; Surendra R Punganuru; Hanumantha Rao Madala; Debasish Basak; Agm Mostofa; Kalkunte S Srivenugopal
Journal:  J Biomed Res       Date:  2016-06-10

8.  Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53.

Authors:  F Su; L E Pascal; W Xiao; Z Wang
Journal:  Oncogene       Date:  2009-10-12       Impact factor: 9.867

Review 9.  Fatty Acids, CD36, Thrombospondin-1, and CD47 in Glioblastoma: Together and/or Separately?

Authors:  Cristiana Tanase; Ana Maria Enciu; Elena Codrici; Ionela Daniela Popescu; Maria Dudau; Ana Maria Dobri; Sevinci Pop; Simona Mihai; Ancuța-Augustina Gheorghișan-Gălățeanu; Mihail Eugen Hinescu
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.